The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Zidesamtinib in TKI-naïve patients with ROS1+ NSCLC: insights from the ARROS-1 trial
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explores results from the tyrosine kinase inhibitor (TKI)-naïve cohort of the ARROS-1 (NCT05118789) trial, evaluating zidesamtinib in patients with ROS1-positive non-small cell lung cancer (NSCLC). The objective response rate was found to be 94% and the complete response rate was 15%. Zidesamtinib showed promising central nervous system (CNS) activity, with all 10 patients with prior CNS metastasis showing an intracranial response and 7 patients experiencing an intracranial complete response. Most treatment-emergent adverse events were low grade, and dose reduction or discontinuation due to these was 12% and 4% respectively. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
